Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Exclusion Criteria

• •Active dermatologic conditions that may confound the diagnosis of AD.
• •Use of tanning beds or phototherapy within 6 weeks prior to randomisation.
• •Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation.
• •Treatment with TCS, TCI, or topical phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomisation.
• •Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents.
• •Active skin infection within 1 week prior to randomisation.
• •Clinically significant infection within 4 weeks prior to randomisation.
• •A helminth parasitic infection within 6 months prior to the date informed consent is obtained.
• •Tuberculosis requiring treatment within the 12 months prior to screening.
• •Known primary immunodeficiency disorder.